MediciNova received positive Optical Coherence Tomography (OCT) results from the company’s SPRINT-MS Phase IIb trial of MN-166 (ibudilast) in multiple sclerosis subjects.

Magnolia Neurosciences, co-founded by Accelerator Life Science Partners and The University of Texas MD Anderson Cancer Center, launched with a $31 million Series A financing.

Akcea and Ionis’ Tegsedi (inotersen) received marketing authorization approval from the European Commission for treating stage 1 or stage 2 polyneuropathy in adults with hATTR.